Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful ...

Six months after suffering a life-threatening stroke, a man achieved his goals of walking his daughter down the aisle and dancing the merengue with her at the wedding. BRANDON, Fla. - For Manuel Vera, ...

The standard treatment for these strokes involves removing the clot using a thin tube (catheter) or a stent, a procedure ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful ...